A Form 4 filed on October 28, 2026 by Rallybio Corp director Wendy Chung reported the exercise of stock options and an acquisition of common stock on October 26, 2026.

Key Highlights

  • Reporting person: Wendy Chung, listed as a Director of Rallybio Corp (NASDAQ:RLYB).
  • Transaction: An option exercise (transaction code M) of 2,062 shares of Common Stock on October 26, 2026.
  • Exercise price: $15.28 per share, with the derivative security listed at a price of $0.
  • Beneficial ownership following transaction: 5,624 shares of Common Stock held directly.
  • Derivative securities remaining: 0 options beneficially owned following the reported transaction.
  • Option origin: The option was granted under the Company's 2021 Equity Incentive Plan, vesting on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders, according to the filing.

Wendy Chung's Option Exercise at Rallybio Corp

According to the Form 4 filed with the SEC on October 28, 2026, Wendy Chung, a director of Rallybio Corp, reported a transaction dated October 26, 2026 involving the exercise of an option to purchase Common Stock. The transaction code recorded is M, indicating an exercise or conversion of a derivative security. The filing identifies the issuer as Rallybio Corp, trading on NASDAQ:RLYB.

The filing discloses that 2,062 shares of Common Stock were acquired at a price of $15.28 per share through the exercise. Following the transaction, Chung's direct beneficial ownership of Common Stock stands at 5,624 shares, as reported in Table I of the filing. Concurrently, Table II shows that the underlying option, which carried an exercise price of $15.28 and an expiration date of May 15, 2034, was reduced to 0 derivative securities beneficially owned after the exercise.

The filing notes in its explanation of responses that "the option was granted under the Company's 2021 Equity Incentive Plan" and that it "vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders." The Form 4 was signed by Jonathan Lieber as Attorney-in-Fact on October 28, 2026, and indicates that Chung filed as a single reporting person.

What Was Disclosed

The filing reports a single option exercise by Rallybio Corp director Wendy Chung on October 26, 2026, covering 2,062 shares of Common Stock at $15.28 per share, leaving her with 5,624 shares of Common Stock and zero remaining options from this grant.